Bumrungrad Hospital Public Company Limited (BUHPF) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Bumrungrad Hospital Public Company Limited $4.66, price $6.00, upside -22.3%, quality 70 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Bumrungrad Hospital Public Company Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $2.62 – $8.17 · fair‑value band $3.12 – $6.24 · the $6.00 price screens above the $4.66 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Bumrungrad Hospital Public Company in your weekly email
Every Wednesday you see whether Bumrungrad Hospital Public Company is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Bumrungrad Hospital Public Company Limited owns and operates hospitals and healthcare centers in Thailand and internationally.
Show more
Bumrungrad Hospital Public Company Limited owns and operates hospitals and healthcare centers in Thailand and internationally. It offers services in the areas of allergy, arrhythmia, behavioural health, breast, home, heart valve, robotic surgery, rehabilitation, spine, pediatrics, colorectal surgery, complex coronary artery intervention, comprehensive sleep, cornea transplant, dental, diagnostic, dialysis, radiology and nuclear medicine, digestive disease, ear, nose, throat, emergency, endocrinology, esperance, diabetes, expatriate liaison, eye, fertility, gastrointestinal motility, health screening, holistic wound care, horizon regional cancer, hyperbaric oxygen therapy, nephrology, neuroscience, orthopaedics, perinatal, plastic surgery, pulmonary, refractive surgery, memory, robotic scoliosis, skin, sports medicine and joint, surgery, travel medicine, urology, scientific wellness, skin and aesthetic, and women's centers. The company also operates breastfeeding, Yangon, COVID-19 recovery, IVF, hearing and balance, medical, new life healthy aging, Parkinson's disease and movement disorders, pride, surgery, and vaccine clinics and centers. In addition, it operates spine institute, heart institute, and intensive care unit; and offers nutrition services, pharmacy services, preventive genomics and integrative medicine services. Bumrungrad Hospital Public Company Limited was founded in 1975 and is based in Bangkok, Thailand.
Stock analysis
Bumrungrad Hospital Public Company Limited (BUHPF) currently trades at $6.00, while our model-based Fair Value estimate is $4.66, implying the stock looks roughly 28.7% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $5.20 per share, and 2 of the 26 models we run sit above the $6.00 price.
Bear case: the Asset-Based group reads lowest at $0.7622, and 24 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: $3.12 (bear) to $6.24 (bull), the price of $6.00 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Bumrungrad Hospital Public Company Limited reported revenue of 25.1B THB in FY2025 versus 12.5B THB in FY2021, a compound +19.2%/yr. Reported net income was 7.5B THB in FY2025, compounding +57.6%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
Key figures
Market cap $5.2B · P/E ratio 20.2 · P/S ratio 6.03 · EPS (TTM) $0.2700 · Net margin 29.9% · Return on equity 24.4% · Return on assets (EBIT) 22.7% · Operating margin 34.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 58 out of 100 (medium confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at −22%, BUHPF screens richer than that median.
Fair Value models
Bear $3.12Fair Value $4.66Bull $6.24
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.94/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−2.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.2%
Start year 2020 (pandemic). Over 10 years: +3.6% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in THB ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in THB: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+43.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+43.9%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.44% vs 8%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → 35%
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes less growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+10.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+5.4%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in THB, Thailand: IMF forecast 1.2% a year to 2030, 1.1% from 2016 to 2025) that is about +8.7% a year for the price and +4.1% for the forecasts.
Compare Bumrungrad Hospital Public Company Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 258 stocks
Beats the industry median on 8/15 measures
A mixed picture versus its industry peers.
Valuation
Quality Score70 · Top 25%
Fair Value upside−22% · Below median
Profitability
Return on equity (TTM)24% · Top 25%
Return on assets16% · Top 25%
Net margin (TTM)30% · Top 25%
Operating margin (TTM)35% · Top 25%
Growth and dividend
Revenue growth1% · Below median
Dividend yield (TTM)91.7% · Top 25%
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Bumrungrad Hospital Public Company Limited Fair Value". https://www.fairvalue-calculator.com/stock/BUHPF
Frequently asked questions
Is Bumrungrad Hospital Public Company Limited (BUHPF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $4.66 versus a price of $6.00, about −22% upside (overvalued).
What is the fair value of BUHPF?
Our model-based fair value for Bumrungrad Hospital Public Company Limited is $4.66 (as of Sep 24, 2026), built from audited fundamentals. The current price: $6.00.
What is the quality score of BUHPF?
Bumrungrad Hospital Public Company Limited has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bumrungrad Hospital Public Company Limited (BUHPF)?
Our model-based price target is the fair value of $4.66 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario $3.12, optimistic scenario $6.24. It is a calculation from audited fundamentals, not an analyst target.
What is the Bumrungrad Hospital Public Company Limited stock forecast for 2026?
Our models put fair value at $4.66, about −22% upside versus a price of $6.00 (overvalued). Cautious scenario $3.12, optimistic scenario $6.24. The calculation is refreshed regularly with new filings.
What is the revenue of Bumrungrad Hospital Public Company Limited (BUHPF)?
Bumrungrad Hospital Public Company Limited reported trailing-twelve-month revenue of about 25.5B THB (latest available figure, as of Sep 24, 2026).
What growth is priced into Bumrungrad Hospital Public Company Limited (BUHPF)?
For today's price to be fair in a discounted-cash-flow model, Bumrungrad Hospital Public Company Limited would have to grow free cash flow by +10.0 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +15.2 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of BUHPF use?
Our models discount Bumrungrad Hospital Public Company Limited at 8.5 %: a base by market capitalisation (mid), damped by beta 0.23, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Bumrungrad Hospital Public Company Limited that is +10.0 % per year a year over ten years, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has Bumrungrad Hospital Public Company Limited (BUHPF) delivered so far?
Over the past 5 years revenue at Bumrungrad Hospital Public Company Limited grew +15.2 % a year. The price currently implies +10.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Bumrungrad Hospital Public Company Limited (BUHPF) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Bumrungrad Hospital Public Company Limited (+10.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Bumrungrad Hospital Public Company Limited (BUHPF)?
The free-cash-flow yield on the price is 3.80 %: that much free cash flow Bumrungrad Hospital Public Company Limited produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Bumrungrad Hospital Public Company Limited (BUHPF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bumrungrad Hospital Public Company Limited it is $4.66 per share (as of Sep 24, 2026), against a price of $6.00. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Bumrungrad Hospital Public Company Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, BUHPF trades above its calculated fair value: price $6.00, fair value $4.66, a gap of about −22% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BUHPF?
No. The price is what the market pays today ($6.00); the fair value is what the company's own numbers justify ($4.66). For Bumrungrad Hospital Public Company Limited the two are $1.34 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bumrungrad Hospital Public Company Limited worth?
The market values Bumrungrad Hospital Public Company Limited at about $5.2B (market capitalisation, as of Sep 24, 2026). Per share that is $6.00; our models calculate a fair value of $4.66 per share.
What do the bullish and bearish scenarios say about BUHPF?
Our models span a range for Bumrungrad Hospital Public Company Limited: cautious scenario $3.12, base $4.66, optimistic $6.24 per share (as of Sep 24, 2026, price $6.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BUHPF?
Bumrungrad Hospital Public Company Limited trades at a price-to-earnings ratio of 20.2 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $4.66 is built from several models across several years. Other multiples: PEG 7.4, P/B 5.7, P/S 6.8, EV/EBITDA 16.4.
What is the PEG ratio of BUHPF?
The PEG ratio of Bumrungrad Hospital Public Company Limited is 7.36 (P/E divided by earnings growth, as of Sep 24, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Bumrungrad Hospital Public Company Limited (BUHPF)?
Balance-sheet figures for Bumrungrad Hospital Public Company Limited (as of Sep 24, 2026): return on equity 24.4%, debt of 0.00 per unit of equity. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
Which stocks are comparable to Bumrungrad Hospital Public Company Limited?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bumrungrad Hospital Public Company Limited stock attractive at the current price?
The data as of Sep 24, 2026: price $6.00, calculated fair value $4.66 (−22%), Quality Score 70/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BUHPF calculated?
We run Bumrungrad Hospital Public Company Limited through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $4.66, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Bumrungrad Hospital Public Company Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bumrungrad Hospital Public Company Limited (BUHPF)?
The closing price on Sep 23, 2026 was $6.00. Our model-based fair value is $4.66, about −22% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bumrungrad Hospital Public Company Limited right now?
A high-quality business (quality 70/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. A fairly wide model range ($3.12 to $6.24) leaves room in how you read the outcome.
Where does the earnings growth of Bumrungrad Hospital Public Company Limited (BUHPF) come from?
Earnings per share at Bumrungrad Hospital Public Company Limited grew +9.6 % a year from 2014 to 2025. Broken into its drivers: revenue per share +4.5 %, EBIT margin +4.0 %, tax rate +0.1 %, residual (interest, one-offs) +0.7 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Bumrungrad Hospital Public Company Limited
How large is the market capitalisation of Bumrungrad Hospital Public Company Limited (BUHPF)?
The market capitalisation of Bumrungrad Hospital Public Company Limited is $5.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bumrungrad Hospital Public Company Limited (BUHPF)?
The price-to-sales ratio of Bumrungrad Hospital Public Company Limited is 6.03 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bumrungrad Hospital Public Company Limited (BUHPF)?
Earnings per share at Bumrungrad Hospital Public Company Limited are $0.2700 (price ÷ EPS = P/E 20.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Bumrungrad Hospital Public Company Limited (BUHPF)?
The net margin of Bumrungrad Hospital Public Company Limited is 29.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bumrungrad Hospital Public Company Limited (BUHPF)?
The return on equity (ROE) of Bumrungrad Hospital Public Company Limited is 24.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bumrungrad Hospital Public Company Limited (BUHPF)?
On an EBIT basis the return on assets of Bumrungrad Hospital Public Company Limited is 22.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bumrungrad Hospital Public Company Limited (BUHPF)?
The operating margin of Bumrungrad Hospital Public Company Limited is 34.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bumrungrad Hospital Public Company Limited (BUHPF)?
Revenue at Bumrungrad Hospital Public Company Limited is growing +0.7% versus a year earlier (3y avg +6.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bumrungrad Hospital Public Company Limited (BUHPF)?
Earnings per share at Bumrungrad Hospital Public Company Limited are growing +3.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Bumrungrad Hospital Public Company Limited (BUHPF) hold?
Bumrungrad Hospital Public Company Limited holds more cash than debt, 7.1B THB net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Bumrungrad Hospital Public Company Limited in the live analysis
One click puts Bumrungrad Hospital Public Company Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Broad data
Sep 24, 2026